Risk for stomatitis-associated adverse events is included as label warnings for other chemotherapies targeting the PI3K/AKT/mTOR pathway, with mTOR-inhibitor-associated stomatitis (mIAS) being well documented in the literature [23]. This evidence concerns the gene AKT1 and stomatitis.